A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors
← catalyst calendarNCT07656727 · readout in 103 d
Sponsored by BioAge Labs, Inc. (industry) · BIOA — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
160estimated
Sites
13
Countries
Puerto Rico, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-06-11 | actual | When the study began enrolling |
| Primary completion | 2026-11-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2026-06-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Obesity and Cardiovascular Risk
Interventions
- Drug: Oral BGE-102
- Drug: Oral Placebo Matching BGE-102
Primary outcomes
what the primary-completion date above is the date OFPercent change in hsCRP (Dose A)
measured Week 12
Percent change in hsCRP (Dose B)
measured Week 12
Percent change in hsCRP (Dose C)
measured Week 12
Permalink · BIOA's whole pipeline · Catalyst calendar · Every registered study · What changed